EQ

Equillium
NASDAQ
2.310
+0.250
+12.14%
After Hours: 2.340 +0.03 +1.30% 18:26 03/28 EDT
OPEN
2.040
PREV CLOSE
2.060
HIGH
2.450
LOW
2.040
VOLUME
386.04K
TURNOVER
0
52 WEEK HIGH
3.250
52 WEEK LOW
0.4500
MARKET CAP
81.44M
P/E (TTM)
-6.0156
1D
5D
1M
3M
1Y
5Y
Buy Rating Affirmed for Equillium Amid Promising Clinical Trials and Potential Financial Upsides
TipRanks · 2d ago
Equillium Shares Fall After Swing to 4Q Loss
The stock was down 18% at $2 on Tuesday. The clinical-stage biotech company reported a loss of $2.3 million in the fourth quarter on lower sales. Shares have more than doubled since the start of the year. Equillium's quarterly revenue fell to $9.2 million.
Dow Jones · 2d ago
Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Westport Fuel Systems Inc. (NASDAQ:WPRT) posts wider-than-expected fourth-quarter loss. Krispy Kreme, Inc. And McDonald's expanded their partnership. Stoke Therapeutics, Inc., shares gained 72.6% to $11.24. C3is Inc. Reported a year-over-year increase in financial results.
Benzinga · 2d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Stoke Therapeutics (NASDAQ:STOK) stock moved upwards by 71.8% to $11.16 during Tuesday's regular session. The company's, Q4 earnings came out 3 days ago. Mesoblast and OpGen shares also moved upwards.
Benzinga · 2d ago
EQ Stock Earnings: Equillium Beats EPS, Beats Revenue for Q4 2023
Equillium reported earnings per share of -7 cents for the fourth quarter of 2023. The company reported revenue of $9.21 million. This was 4.08% better than the analyst estimate of $8.85 million. Equillium also reported results for the third quarter.
Investorplace · 3d ago
Equillium, Inc. (EQ) Reports Q4 Loss, Tops Revenue Estimates
NASDAQ · 3d ago
Equillium Inc reports results for the quarter ended in December - Earnings Summary
Equillium Inc reports results for the quarter ended in December. Revenue fell 41.6% to $9.21 million from a year ago. The company reported a quarterly loss of $2.33 million. Shares had risen by 290.0% this quarter.
Reuters · 3d ago
Equillium Q4 2023 GAAP EPS $(0.07) Beats $(0.17) Estimate, Sales $9.200M Beat $6.425M Estimate
Equillium (NASDAQ:EQ) reported quarterly losses of $0.07 per share. The company reported quarterly sales of $9.200 million which beat the analyst consensus estimate of $6.425 million. Equillium also reported a 41.62 percent decrease in sales from the same period last year.
Benzinga · 3d ago
More
About EQ
Equillium, Inc. is a clinical-stage biotechnology company that develops therapeutics to treat severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical needs. Its pipeline consists of novel, first-in-class immunomodulatory assets targeting immuno-inflammatory pathways. EQ101 is a tri-specific cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15, which is under evaluation in a Phase II clinical study of patients with alopecia areata. EQ102 is a bi-specific cytokine inhibitor that selectively targets IL-15 and IL-21 and is under evaluation in a Phase I first-in-human clinical study that includes healthy volunteers and celiac disease patients. Itolizumab is a monoclonal antibody that targets the CD6-ALCAM signaling pathway for the modulation of effector T cells and is under evaluation in a Phase III clinical study of patients with acute graft-versus-host disease (aGVHD) and a Phase Ib clinical study of patients with lupus/lupus nephritis.

Webull offers Equillium Inc stock information, including NASDAQ: EQ real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, EQ stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading EQ stock methods without spending real money on the virtual paper trading platform.